Unum Therapeutics Revenue and Competitors

Unum Therapeutics is a Cambridge, Massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual's cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum's approach is not restricted by antigens and may have applications for treating many types of cancers. Unum's vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. Unum's lead program based on ACTR technology is currently in Phase I clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, Unum is actively working with partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Unum expects to rapidly advance multiple proprietary combinations into clinical testing within the next few years.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power